FINWIRES · TerminalLIVE
FINWIRES

$UTHR

46 stories mentioning UTHR

Every FINWIRES story that references UTHR, newest first.

Insider Trading

United Therapeutics Insider Sold Shares Worth $5,185,365, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 10, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,185,365. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000074/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,218,534, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 09, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,218,534. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000073/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,201,110, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 08, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,201,110. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000072/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,114,742, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 02, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,114,742. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000068/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,261,365, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 29, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,261,365. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000065/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,466,283, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 27, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,466,283. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000063/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,729,359, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on May 26, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,729,359. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000021/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,393,558, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 22, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,393,558. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000060/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,641,130, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on May 21, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,641,130. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000020/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,359,011, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 21, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,359,011. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000059/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,671,399, According to a Recent SEC Filing

Paul A Mahon, Executive Vice President & General Counsel, on May 21, 2026, sold 8,300 shares in United Therapeutics (UTHR) for $4,671,399. Following the Form 4 filing with the SEC, Mahon has control over a total of 45,172 common shares of the company, with 45,172 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123158926000012/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,376,814, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 20, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,376,814. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000058/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,395,399, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 19, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,395,399. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000057/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,397,077, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on May 15, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,397,077. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000055/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,744,746, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on May 14, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,744,746. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000018/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,497,166, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 13, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,497,166. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000053/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,785,775, According to a Recent SEC Filing

James Edgemond, Chief Financial Officer and Treasurer, on May 07, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,785,775. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000016/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,496,084, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on May 07, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,496,084. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000049/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,600,468, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 06, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,600,468. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000048/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,870,054, According to a Recent SEC Filing

Paul A Mahon, Executive Vice President & General Counsel, on May 07, 2026, sold 8,300 shares in United Therapeutics (UTHR) for $4,870,054. Following the Form 4 filing with the SEC, Mahon has control over a total of 45,172 common shares of the company, with 45,172 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123158926000011/xslF345X05/primarydocument.xml

$UTHR

Showing 1-20 of 46